Beskrivelse
Krav
Fullmektig i Norge:
Org.nummer: 979993269
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2014.08.22, US 201462040918 P
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2013 (2013-11), TAKAMATSU HIROYUKI ET AL: "A Comparison Between Next-Generation Sequencing and ASO-qPCR For Minimal Residual Disease Detection In Multiple Myeloma: The Clinical Value In ASCT Setting", XP002746645, Database accession no. PREV201400360880 (B1)
DIMOPOULOS MELETIOS A. ET AL: "Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth", BRITISH JOURNAL OF HAEMATOLOGY, vol. 178, no. 6, 5 July 2017 (2017-07-05), pages 896-905, XP055777239, GB ISSN: 0007-1048, DOI: 10.1111/bjh.14787 Retrieved from the Internet: URL:https://api.wiley.com/onlinelibrary/td m/v1/articles/10.1111%2Fbjh.14787> (B1)
Kuznar Wayne: "Maintenance Therapy With Elotuzumab/Lenalidomide Boosts Response Conversions in Multiple Myeloma", , 14 December 2017 (2017-12-14), pages 1-6, XP055777221, Retrieved from the Internet: URL:https://www.targetedonc.com/view/maint enance-therapy-with-elotuzumablenalidomide -boosts-response-conversions-in-multiple-m yeloma [retrieved on 2021-02-17] (B1)
WO-A1-2008/019378 (B1)
N. C. MUNSHI ET AL: "Minimal Residual Disease in Multiple Myeloma", JOURNAL OF CLINICAL ONCOLOGY, vol. 31, no. 20, 10 July 2013 (2013-07-10) , pages 2523-2526, XP055221099, US ISSN: 0732-183X, DOI: 10.1200/JCO.2013.49.2124 (B1)
NIELS WCJ VAN DE DONK: "New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients", EXPERT OPINION ON PHARMACOTHERAPY, ASHLEY PUBLICATIONS LTD, LONDON, UK, vol. 14, no. 12, 1 August 2013 (2013-08-01), pages 1569-1573, XP009180238, ISSN: 1465-6566, DOI: 10.1517/14656566.2013.805746 [retrieved on 2013-05-31] (B1)
Philip L Mccarthy: "Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma", The New England Journal of Medicine 366;19, 10 May 2012 (2012-05-10), pages 1770-1781, XP055220858, Retrieved from the Internet: URL:http://www.nejm.org/doi/pdf/10.1056/NE JMoa1114083 [retrieved on 2015-10-14] (B1)
Magen Hila: "Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment", Ther Adv Hematol, 1 January 2016 (2016-01-01), pages 187-195, XP055777063, DOI: 10.1177/2040620716652862Therapeutic Retrieved from the Internet: URL:https://journals.sagepub.com/doi/pdf/1 0.1177/2040620716652862 [retrieved on 2021-02-17] (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Varsel om betaling av første årsavgift (3319) (PTEP3182996)
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210) (PTEP3182996)
|
Innkommende, AR541250672
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 10. avg. år (EP) | 2024.08.09 | 4160 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 9. avg. år (EP) | 2023.07.05 | 2850 | ENVOY INTERNATIONAL LIMITED | Betalt og godkjent |
32303138 expand_more expand_less | 2023.03.29 | 5500 | BRYN AARFLOT AS | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|